Protagenic Therapeutics intends to submit an Investigational New Drug (IND) application for PT00114 by year-end 2026 after receiving positive feedback from the FDA. The successful IND could lead to first patient dosing for generalized anxiety disorder in the first half of 2027.

Key Highlights

  • Protagenic Therapeutics aims to submit an IND for PT00114 before the end of 2026.
  • The FDA raised no objections to the design of the planned Phase 1 program for PT00114.
  • Protagenic Therapeutics, Inc. (OTC: PTIX) announced it plans to submit an Investigational New Drug (IND) application for PT00114 by the end of 2026.

Protagenic Therapeutics, Inc. (OTC: PTIX) announced it plans to submit an Investigational New Drug (IND) application for PT00114 by the end of 2026. The positive feedback from the FDA signals a critical step forward for the company in bringing this investigational therapy to market.

FDA Feedback Received

The FDA provided written responses confirming no objections to the Phase 1 program design for PT00114. The feedback particularly noted no clinical holds and stated that the proposed strategies for potency, comparability, and chemistry, manufacturing, and controls (CMC) appeared reasonable in supporting an IND submission. The FDA's insights enable Protagenic to advance its development plan without any identified deficiencies that could hinder submission.

This official response is vital for the progression of PT00114 and affirms the groundwork Protagenic has laid for this potential treatment.

Clinical Development Background

PT00114 has previously undergone Phase 1 studies for both single and multiple ascending doses, conducted outside the United States. These studies demonstrated that PT00114 was well tolerated among participants, with no serious adverse events reported. These findings offer a foundation for the upcoming clinical development in the U.S. While past studies were not conducted under an IND, the FDA’s guidance now allows these clinical experiences to be incorporated into the domestic program.

This translates into refined specification and expanded cohorts for the anticipated IND submission.

Importance of Timely Submission

GAD, impacting approximately 6.8 million adults in the U.S. alone, remains a clinical area with significant unmet needs. The absence of new approved medications specifically for GAD in nearly two decades underlines the importance of advancing innovative treatments. If PT00114's proposed mechanism proves effective, it could offer a novel therapeutic approach for patients currently underserved by existing treatments.

Future Developments to Monitor

The next key milestone for Protagenic will be the IND submission by the end of 2026. This is contingent upon the completion of necessary CMC, manufacturing, and nonclinical activities as dictated by the regulatory framework. As the company navigates this pathway, monitoring the FDA's review process will be important, as any additional requests for data or insights could affect the timeline.

Continued updates will shed light on the progress toward first patient dosing, offering Stakeholders insight into the future of PT00114 and its potential impact within neuropsychiatric treatment paradigms.